Differential characteristics of Waldenström macroglobulinemia according to patterns of familial aggregation

Blood

Volumn 115, Issue 22, 2010, Pages 4464-4471

  Royer, Regan H ^a   Koshiol, Jill ^a   Giambarresi, Therese R ^b   Vasquez, Linda G ^b   Pfeiffer, Ruth M ^a   McMaster, Mary L ^a,c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WESTAT   (United States)

^c U S PUBLIC HEALTH SERVICE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CELL AGGREGATION; CLINICAL FEATURE; CONTROLLED STUDY; ENVIRONMENTAL FACTOR; FAMILY HISTORY; FEMALE; HEREDITY; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; RACE DIFFERENCE; WALDENSTROEM MACROGLOBULINEMIA; ADOLESCENT; AUTOIMMUNE DISEASE; CONFIDENCE INTERVAL; ENVIRONMENTAL EXPOSURE; GENETICS; MIDDLE AGED; NATIONAL HEALTH ORGANIZATION; OCCUPATIONAL EXPOSURE; REGISTER; RISK; RISK FACTOR; UNITED STATES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AUTOIMMUNE DISEASES; CONFIDENCE INTERVALS; ENVIRONMENTAL EXPOSURE; FEMALE; HUMANS; INFECTION; MALE; MIDDLE AGED; NATIONAL CANCER INSTITUTE (U.S.); OCCUPATIONAL EXPOSURE; ODDS RATIO; QUESTIONNAIRES; REGISTRIES; RISK FACTORS; UNITED STATES; WALDENSTROM MACROGLOBULINEMIA; YOUNG ADULT;

EID: 77953934879     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-10-247973     Document Type: Article

References (44)

1. Owen RG, Treon SP, Al Katib A, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003;30(2):110-115.
2. Berger F, Isaacson PG, Piris MA, et al. Lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:132-134.
3. Vijay A, Gertz MA. Waldenstrom macroglobulinemia. Blood. 2007;109(12):5096-5103.
4. American Cancer Society. Detailed guide: Waldenstrom macroglobulinemia. http://www.cancer.org/docroot/CRI/CRI-2-3x.asp?dt=76. Accessed December 22, 2009.
5. Kyle RA, Therneau TM, Rajkumar SV, et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood. 2003;102(10):3759- 3764.
6. Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354(13):1362-1369.
7. Groves FD, Travis LB, Devesa SS, Ries LAG, Fraumeni JF Jr. Waldenström's macroglobulinemia: incidence patterns in the United States, 1988-1994. Cancer. 1998;82(6):1078-1081.
8. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346(8):564-569.
9. James JM, Brouet JC, Orvoenfrija E, et al. Waldenstrom's macroglobulinaemia in a bird breeder: a case history with pulmonary involvement and antibody activity of the monoclonal IgM to canary's droppings. Clin Exp Immunol. 1987;68(2):397-401.
10. Williamson LM, Greaves M, Worters JR, Harling CC, Waters JR. Waldenstrom's macroglobulinaemia: three cases in shoe repairers. BMJ. 1989;298(6672):498-499.
11. Tepper A, Moss CE. Waldenstrom's macroglobulinemia: search for occupational exposure. J Occup Med. 1994;36(2):133-136.
12. Linet MS, Humphrey RL, Mehl ES, et al. A case-control and family study of Waldenstrom's macroglobulinemia. Leukemia. 1993;7(9):1363-1369.
13. Risch NJ, Whittemore AS. Genetic concepts and methods in epidemiologic research. In: Schottenfeld D, Fraumeni JFJ, eds. Cancer Epidemiology and Prevention. New York, NY: Oxford University Press; 2006:89-98.
14. Renier G, Ifrah N, Chevailler A, et al. Four brothers with Waldenstrom's macroglobulinemia. Cancer. 1989;64(7):1554-1559.
15. Fine JM, Muller JY, Rochu D, et al. Waldenstrom's macroglobulinemia in monozygotic twins. Acta Med Scand. 1986;220(4):369-373.
16. Massari R, Fine JM, Metais R. Waldenstrom's macroglobulinæmia observed in two brothers. Nature. 1962;196:176-178.
17. Fine JM, Lambin P, Massari M, Leroux P. Malignant evolution of asymptomatic monoclonal IgM after seven and fifteen years in two siblings of a patient with Waldenström's macroglobulinemia. Acta Med Scand. 1982;211(3):237-239.
18. Blattner WA, Garber JE, Mann DL, et al. Waldenstrom's macroglobulinemia and autoimmune disease in a family. Ann Intern Med. 1980;93(6):830-832.
19. Altieri A, Bermejo JL, Hemminki K. Familial aggregation of lymphoplasmacytic lymphoma with non-Hodgkin lymphoma and other neoplasms. Leukemia. 2005;19(12):2342-2343. (Pubitemid 41741634)
20. Kristinsson SY, Bjorkholm M, Goldin LR, et al. Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden. Blood. 2008;112(8):3052-3056.
21. Treon SP, Hunter ZR, Aggarwal A, et al. Characterization of familial Waldenstrom's macroglobulinemia. Ann Oncol. 2006;17(3):488-494.
22. Ogmundsdóttir HM, Johannesson G, Sveinsdottir S, et al. Familial macroglobulinaemia: hyperactive B-cells but normal natural killer function. Scand J Immunol. 1994;40(2):195-200.
23. McMaster ML. Familial Waldenstrom's macroglobulinemia. Semin Oncol. 2003;30(2):146-152.
24. McMaster ML, Csako G, Giambarresi TR, et al. Long-term evaluation of three multiple-case Waldenstrom macroglobulinemia families. Clin Cancer Res. 2007;13(17):5063-5069.
25. McMaster ML, Csako G. Protein electrophoresis, immunoelectrophoresis and immunofixation electrophoresis as predictors for high-risk phenotype in familial Waldenstrom macroglobulinemia. Int J Cancer. 2008;122(5):1183-1188.
26. McMaster ML, Caporaso N. Waldenstrom macroglobulinaemia and IgM monoclonal gammopathy of undetermined significance: emerging understanding of a potential precursor condition. Br J Haematol. 2007;139(5):663-671.
27. Mellemkjaer L, Pfeiffer RM, Engels EA, et al. Autoimmune disease in individuals and close family members and susceptibility to non-Hodgkin's lymphoma. Arthritis Rheum. 2008;58(3):657-666.
28. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73(1):13-22.
29. Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst. 1994;86(21):1600-1608.
30. Chatterjee N, Hartge P, Cerhan JR, et al. Risk of non-Hodgkin's lymphoma and family history of lymphatic, hematologic, and other cancers. Cancer Epidemiol Biomarkers Prev. 2004;13(9):1415-1421.
31. Wang SS, Slager SL, Brennan P, et al. Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10211 cases and 11905 controls from the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;109(8):3479-3488.
32. Wagner SD, Martinelli V, Luzzatto L. Similar patterns of Vk gene usage but different degrees of somatic mutation in hairy-cell leukemia, prolymphocytic leukemia, Waldenstroms macroglobulinemia, and myeloma. Blood. 1994;83(12):3647-3653.
33. Aoki H, Takishita M, Kosaka M, Saito S. Frequent somatic mutations in D and/or JH segments of Ig gene in Waldenstrom's macroglobulinemia and chronic lymphocytic leukemia (CLL) with Richter's syndrome but not in common CLL. Blood. 1995;85(7):1913-1919.
34. Giordano TP, Henderson L, Landgren O, et al. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA. 2007;297(18):2010-2017.
35. Koshiol J, Gridley G, Engels EA, McMaster ML, Landgren O. Chronic immune stimulation and subsequent Waldenstrom macroglobulinemia. Arch Int Med. 2008;168(17):1903-1909.
36. De Sanjose S, Benavente Y, Vajdic CM, et al. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. Clinl Gastroenterol Hepatol. 2008;6(4):451-458.
37. Suarez F, Lortholary O, Hermine O, Lecuit M. Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood. 2006;107(8):3034-3044.
38. Brown LM, Gridley G, Check D, Landgren O. Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. Blood. 2008;111(7):3388-3394.
39. Landgren O, Rapkin JS, Mellemkjaer L, et al. Respiratory tract infections in the pathway to multiple myeloma: a population-based study in Scandinavia. Haematologica. 2006;91(12):1697-1700.
40. Filipovich AH, Mathur A, Kamat D, Shapiro RS. Primary immunodeficiencies: genetic risk-factors for lymphoma. Cancer Res. 1992;52(19 suppl):S5465-S5467.
41. Ekström Smedby KE, Vajdic CM, Falster M, et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph consortium. Blood. 2008;111(8):4029-4038.
42. Hauswirth AW, Skrabs C, Schutzinger C, et al. Autoimmune thrombocytopenia in non-Hodgkin's lymphomas. Haematologica. 2008;93(3):447-450.
43. Alexander DD, Mink PJ, Adami HO, et al. The non-Hodgkin lymphomas: a review of the epidemiologic literature. Int J Cancer. 2007;120(suppl 12):1-39.
44. Grulich AE, Vajdic CM. The epidemiology of non-Hodgkin lymphoma. Pathology. 2005;37(6):409-419.